Investment
Features
FeesSafety
Academy
More
Pluang+

Arkansas foreign Bitcoin mining ban remains blocked as appeals court reviews injunction

Market News
20 Oct 2026
Crypto Briefing
View Source
Neutral
Arkansas foreign Bitcoin mining ban remains blocked as appeals court reviews injunction

Arkansas's laws banning foreign-controlled companies from owning Bitcoin mining operations remain blocked by a federal injunction. The Eighth Circuit Court is reviewing whether to lift this injunction, which was initially granted after Jones Eagle LLC challenged the laws as conflicting with federal foreign investment rules. The state argues the laws regulate land use and align with national security, while Jones Eagle claims the laws interfere with federal foreign policy. The court's decision will impact the enforcement of Arkansas's restrictions and could set a precedent for other states considering similar measures.

Arkansas's foreign Bitcoin mining ownership law remains blocked as the appeals court considers the case. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 21, 2026 03:41 WIB: out of 50 major cryptocurrencies priced on Pluang, 45 rose and 4 fell today. Notable movers include SXP (Solar) down 46.27% at Rp37 with a typical hold time of 94 days, COMP (Compound) up 23.17% at Rp475.589 with 32% sell and 68% buy order activity, and THETA (Theta Network) up 11.62% at Rp3.746 with 100% sell order activity and a typical hold time of 78 days.

More News

Moody's Q3 2026 earnings preview highlights credit ratings and AI-driven analytics growth.

Moody's Q3 2026 earnings preview highlights credit ratings and AI-driven analytics growth.

Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...

Company Fundamentals
Neutral
1 hour ago
Raymond James raises Rapport Therapeutics price target to $86 after positive Phase 2 trial for bipolar mania drug.

Raymond James raises Rapport Therapeutics price target to $86 after positive Phase 2 trial for bipolar mania drug.

Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...

Analyst Insights
Bullish
1 hour ago
Heartland Express Q3 revenue falls 8.7%, misses estimates but returns to profit

Heartland Express Q3 revenue falls 8.7%, misses estimates but returns to profit

Heartland Express reported a third-quarter 2026 revenue decline of 8.7% to $179.5 million, missing analyst estimates. Despite lower revenue, the company returned to profitability with a net income of $1.0 million, compared to a loss last year. The op...

Company Fundamentals
Bearish
1 hour ago
CMMB opens new Distribution Center at Brethren Service Center to boost global medicine access.

CMMB opens new Distribution Center at Brethren Service Center to boost global medicine access.

Catholic Medical Mission Board (CMMB) held a ribbon-cutting ceremony for its new Distribution Center at the Brethren Service Center in New Windsor, Maryland. This move enhances CMMB's Access to Medicines Program by expanding operational capacity and ...

Others
Neutral
2 hours ago
Myriad Genetics upgraded to Neutral as it sells prenatal unit to Labcorp for $210M.

Myriad Genetics upgraded to Neutral as it sells prenatal unit to Labcorp for $210M.

Piper Sandler upgraded Myriad Genetics from Underweight to Neutral and set a $5.00 price target after the company agreed to sell its prenatal health testing business to Labcorp for $210 million in cash. This sale includes several prenatal tests and i...

Analyst Insights
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App